Portal de Periódicos da CAPES

Studies with the experimental antitumor agent 4-aminopyrazolo[3,4-d]pyrimidine

1960; Wiley; Volume: 13; Issue: 3 Linguagem: Inglês

10.1002/1097-0142(196005/06)13

1097-0142

Richard K. Shaw, Raphael N. Shulman, Jack D. Davidson, David P. Rall, Emil Frei,

Synthesis and Biological Evaluation

CancerVolume 13, Issue 3 p. 482-489 ArticleFree Access Studies with the experimental antitumor agent 4-aminopyrazolo[3,4-d]pyrimidine Richard K. Shaw M.D., Richard K. Shaw M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorRaphael N. Shulman M.D., Raphael N. Shulman M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorJack D. Davidson M.D., Jack D. Davidson M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorDavid P. Rall M.D., David P. Rall M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorEmil Frei III M.D., Emil Frei III M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this author Richard K. Shaw M.D., Richard K. Shaw M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorRaphael N. Shulman M.D., Raphael N. Shulman M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorJack D. Davidson M.D., Jack D. Davidson M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorDavid P. Rall M.D., David P. Rall M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this authorEmil Frei III M.D., Emil Frei III M.D. National Cancer Institute and the National Institute of Arthritis and Metabolic Diseases, of the National Institutes of Health, Public Health Service, Bethesda, Md.Search for more papers by this author First published: May/June 1960 https://doi.org/10.1002/1097-0142(196005/06)13:3 3.0.CO;2-SCitations: 22AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1. Biggs, R., and Douglas, A. S.: Thromboplastin generation test. J. Clin. Path. 6: 23– 29, 1953. 2. Biggs, R., and Macfarlane, R. G.: Human Blood Coagulation and Its Disorders, 2d ed. Springfield, Ill. Charles C Thomas, Publisher. 1957. 3. Feigelson, P., and Davidson, J. D.: Studies on inhibition of xanthine oxidase by 8-azaguanine and pyrazolopyrimidines. Proc. Am. A. Cancer Res. 2: 108, 1956. 4. Feigelson, P., and Davidson, J. D.: Metabolism of pyrazolo(3,4-d)pyrimidines by rat. Cancer Res. 18: 226– 228, 1958. 5. Feigelson, P., Davidson, J. D., and Robins, R. K.: Pyrazolopyrimidines as inhibitors and substrates of xanthine oxidase. J. Biol. Chem. 226: 993– 1000, 1957. 6. Finkbiner, R. B., McGovern, J. J., Goldstein, R., and Bunker, J. P.: Coagulation defects in liver disease and response to transfusion during surgery. Am. J. Med. 26: 199– 213, 1959. 7. Fuerst, R., Somers, C. E., and Hsu, T. C.: Studies on 4-aminopyrazolo(3,4-d)pyrimidine; growth inhibition and relief in Neurospora crassa. J. Bact. 72: 387– 393, 1956. 8. Goldin, A., Venditti, J. M., Humphreys, S. R., and Mantel, N.: Quantitative evaluation of chemotherapeutic agents against advanced leukemia in mice. J. Nat. Cancer Inst. 21: 495– 511, 1958. 9. Graham, J. B., Penick, G. D., and Brinkhous, K. M.: Estimation of antihemophilic activity by prothrombin utilization technique. In L. M. Tocantins, Ed.: The Coagulation of Blood; Methods of Study. New York, N.Y. Grune & Stratton, Inc. 1955; pp. 77– 80. 10. Hsu, T. C., Robins, R. K., and Cheng, C. C.: Studies on 4APP; antineoplastic action in vitro. Science 123: 848, 1956. 11. Jenkins, J. S.: Thromboplastic activity of Russell's viper venom and its relationship to factor VII. J. Clin. Path. 7: 287– 289, 1954. 12. Krakoff, I. H., and Karnofsky, D. A.: Preliminary results with 4-aminopyrazolo-pyrimidine in humans. Proc. Am. A. Cancer Res. 2: 223, 1957. 13. Parr, C. W.: Separation of sugars and of sugar phosphates by gradient elution from ion exchange columns. [Abstr.] Biochem. J. 55: xxvii– xxviii, 1954. 14. Quick, A. J.: Clinical application of hippuric acid and prothrombin tests. Am. J. Clin. Path. 10: 222– 233, 1940. 15. Ratnoff, O. D.: Thrombin accelerator; clotting factor of plasma deficient in cirrhosis of liver, multiple myeloma, and eclampsia. J. Lab. Clin. Med. 42: 933– 934, 1953. 16. Robins, R. K.: Potential purine antagonists; I, synthesis of some 4,6-substituted pyrazolo[3,4-d]pyrimidines. J. Am. Chem. Soc. 78: 784– 790, 1956. 17. Scholler, J., Philips, F. S., and Sternberg, S. S.: Production of fatty livers by 4-aminopyrazolo-(3,4-d)-pyrimidine; toxological and pathological studies. Proc. Soc. Exper. Biol. & Med. 93: 398– 402, 1956. 18. Skipper, H. E., Robins, R. K., Thomson, J. R., Cheng, C. C.; Brockman, R. W. and Schabel, F. M., Jr.: Structure-activity relationships observed on screening series of pyrazolopyrimidines against experimental neoplasms. Cancer Res. 17: 579– 596, 1957. 19. Somers, C. E., Fuerst, R., and Hsu, T. C.: Studies on 4-aminopyrazolo(3,4-d)pyrimidine; structural relationships among inhibiting and relieving agents in Neurospora, Antibiotics & Chemother. 7: 363– 373, 1957. 20. Stefanini, M.: New 1-stage procedures for quantitative determination of prothrombin and labile factor. Am. J. Clin. Path. 20: 233– 240, 1950. 21. Stefanini, M., and Dameshek, W.: The Hemorrhagic Disorders; a Clinical and Therapeutic Approach. New York, N.Y. Grune & Stratton, Inc. 1955. 22. Sugiura, K.: Relative sensitivity of solid and ascites forms of Sarcoma 180 and Ehrlich carcinoma to inhibitory compounds. Ann. New York Acad. Sc. 76: 575– 585, 1958. 23. Tarnowski, G. S., and Stock, C. C.: Chemotherapy studies on RC and S 790 mouse mammary carcinomas. Cancer Res. 18 (suppl.): 1– 48, 1958; 10. 24. Venditti, J. M., and Goldin, A.: Personal communication. 25. Warner, E. D., Brinkhous, K. M., and Smith, H. P.: Titration of prothrombin in certain plasmas. [Abstr.] Arch. Path. 18: 587, 1934. 26. Weissmann, B., Bromberg, P. A., and Gutman, A. B.: Purine bases of human urine; I, separation and identification. J. Biol. Chem. 224: 407– 422, 1957. Citing Literature Volume13, Issue3May/June 1960Pages 482-489 ReferencesRelatedInformation